Autres langues Genmab A/S Nasdaq

Actions

GMAB

US3723032062

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/07/2026			Varia. 5j.	Varia. 1 janv.
29,00 ^USD	-2,62%		+1,70%	-5,84%

10/07	Actions nordiques en Amérique du Nord - Astra Zeneca progresse de 0,6 %	FW
08/07	Actions nordiques en Amérique du Nord - Ericsson recule de 0,7 %	FW

Autres langues

07/07	Chip-Kater an der Wall Street
07/07	Afternoon Meeting: Los semiconductores se enfrían en Wall Street
07/07	Exchange-Traded Funds Lower, Equity Futures Mixed Amid Caution Over Chip Sector Outlook
07/07	Wall Street's Chip Chill
07/07	Genmab Secures EU Approval for Drug Combination Intended for Relapsed or Refractory Follicular Lymphoma
07/07	Morning Meeting: Märkte im Takt Koreas
07/07	Markets on Korean time
07/07	Genmab Wins EU Approval for Follicular Lymphoma Treatment Combination
06/07	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06/07	Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06/07	Genmab Announces Tepkinly in Combination with Lenalidomide and Rituximab Is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
30/06	Healthcare Stocks Fall as Markets Rotate Back to Tech -- Healthcare Roundup
30/06	Schweizer Aktien Schluss: SMI nach Rekord von Schwergewichten heruntergezogen
30/06	Aktien Schweiz gehen nach Allzeithoch knapp behauptet aus dem Tag
30/06	KI-Aktien beenden das Quartal mit und ohne Applaus
30/06	Afternoon Meeting: Los valores de IA cierran el trimestre con indiferencia
30/06	AI stocks are ending the quarter with a shrug
30/06	Europa trotz fehlender Impulse im Plus
30/06	U.S. Futures Mixed, European Stocks Rise
30/06	Morning Meeting: Trimestre exuberante para la renta variable, pero ¿racional?
30/06	An exuberant quarter for equities, but not an irrational one?
30/06	Genmab Says Epcoritamab Combo Improves Progression-free Survival in Phase 3 Blood Cancer Study
29/06	Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial
29/06	AbbVie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial
29/06	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival